Vanessa Guerreiro1,2, João Sérgio Neves3,4, Daniela Salazar3,4, Maria João Ferreira3,4, Sofia Castro Oliveira3,4, Pedro Souteiro3,4, Jorge Pedro3,4, Daniela Magalhães3,4, Ana Varela3,4, Sandra Belo3,4, Paula Freitas3,4,5,6, Davide Carvalho3,4. 1. Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar São João, Porto, Portugal, vanessa.a.guerreiro@gmail.com. 2. Faculty of Medicine, University of Porto, Porto, Portugal, vanessa.a.guerreiro@gmail.com. 3. Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar São João, Porto, Portugal. 4. Faculty of Medicine, University of Porto, Porto, Portugal. 5. Instituto de Investigação e Inovação em Saúde, University of Porto, Porto, Portugal. 6. Multidisciplinary Group for Surgical Management of Obesity, Centro Hospitalar São João, Porto, Portugal.
Abstract
INTRODUCTION: Bariatric surgery is an effective treatment for morbid obesity and its metabolic related comorbidities. However, the literature reports inconsistent results regarding weight loss (WL) and the resolution of comorbidities associated with obesity. OBJECTIVE: We aim to evaluate long-term differences in WL between different surgical techniques and the impact of each surgical technique on metabolic parameters (type 2 diabetes mellitus [T2DM], dyslipidemia,hypertension, and metabolic syndrome). We also aim to evaluate the effect of baseline clinical characteristics in WL and in the evolution of metabolic syndrome (MetS) components. Our hypothesis is that different types of surgery have different effects on WL and the prevalence of comorbidities over time. METHODS: We retrospectively evaluated WL and metabolic parameter remission (T2DM, dyslipidemia, hypertension, and MetS) during 4 years in 1,837 morbidly obese patients (females, 85%; age, 42.5 ± 10.6 years; BMI, 44.0 ± 5.8) who underwent bariatric surgery (Roux-en-Y gastric bypass [RYGB], laparoscopic sleeve gastrectomy [LSG], and laparoscopic adjustable gastric band [LAGB]). RESULTS: The mean percentage of WL for RYGB, LSG, and LAGB was, respectively, 32.9 ± 8.7, 29.8 ± 9.8, and 16.2 ± 9.6 at 12 months and 30.6 ± 9.1, 22.7 ± 10.0, and 15.8 ± 10.8 at 48 months (p < 0.001), even after adjustment for baseline weight, BMI, age, and sex (p < 0.001). Women had more WL during the first 36 months (p = 0.013 and 0.007 at 12 and 36 months, respectively) and older patients had less WL compared to younger ones (p <0.001), except at 48 months. Patients with T2DM had less WL than those without diabetes after adjustment (sex, age, and surgical technique) during the same period. Patients with hypertension had less WL at 12 months (p = 0.009) and MetS at 24 months (p = 0.020) compared to those without these comorbidities. There was no significant difference regarding the presence of dyslipidemia in WL. The RYGB group showed better results for MetS resolution. CONCLUSION: During the 4-year follow-up, RYGB was the surgical procedure that caused the highest WL and MetS resolution.
INTRODUCTION: Bariatric surgery is an effective treatment for morbid obesity and its metabolic related comorbidities. However, the literature reports inconsistent results regarding weight loss (WL) and the resolution of comorbidities associated with obesity. OBJECTIVE: We aim to evaluate long-term differences in WL between different surgical techniques and the impact of each surgical technique on metabolic parameters (type 2 diabetes mellitus [T2DM], dyslipidemia,hypertension, and metabolic syndrome). We also aim to evaluate the effect of baseline clinical characteristics in WL and in the evolution of metabolic syndrome (MetS) components. Our hypothesis is that different types of surgery have different effects on WL and the prevalence of comorbidities over time. METHODS: We retrospectively evaluated WL and metabolic parameter remission (T2DM, dyslipidemia, hypertension, and MetS) during 4 years in 1,837 morbidly obesepatients (females, 85%; age, 42.5 ± 10.6 years; BMI, 44.0 ± 5.8) who underwent bariatric surgery (Roux-en-Y gastric bypass [RYGB], laparoscopic sleeve gastrectomy [LSG], and laparoscopic adjustable gastric band [LAGB]). RESULTS: The mean percentage of WL for RYGB, LSG, and LAGB was, respectively, 32.9 ± 8.7, 29.8 ± 9.8, and 16.2 ± 9.6 at 12 months and 30.6 ± 9.1, 22.7 ± 10.0, and 15.8 ± 10.8 at 48 months (p < 0.001), even after adjustment for baseline weight, BMI, age, and sex (p < 0.001). Women had more WL during the first 36 months (p = 0.013 and 0.007 at 12 and 36 months, respectively) and older patients had less WL compared to younger ones (p <0.001), except at 48 months. Patients with T2DM had less WL than those without diabetes after adjustment (sex, age, and surgical technique) during the same period. Patients with hypertension had less WL at 12 months (p = 0.009) and MetS at 24 months (p = 0.020) compared to those without these comorbidities. There was no significant difference regarding the presence of dyslipidemia in WL. The RYGB group showed better results for MetS resolution. CONCLUSION: During the 4-year follow-up, RYGB was the surgical procedure that caused the highest WL and MetS resolution.
Authors: Pedro Souteiro; Sandra Belo; João Sérgio Neves; Daniela Magalhães; Rita Bettencourt Silva; Sofia Castro Oliveira; Maria Manuel Costa; Ana Saavedra; Joana Oliveira; Filipe Cunha; Eva Lau; César Esteves; Paula Freitas; Ana Varela; Joana Queirós; Davide Carvalho Journal: Obes Surg Date: 2017-02 Impact factor: 4.129
Authors: Filipe M Cunha; Joana Oliveira; John Preto; Ana Saavedra; Maria M Costa; Daniela Magalhães; Eva Lau; Rita Bettencourt-Silva; Paula Freitas; Ana Varela; Davide Carvalho Journal: Obes Surg Date: 2016-05 Impact factor: 4.129
Authors: Philip R Schauer; Bartolome Burguera; Sayeed Ikramuddin; Dan Cottam; William Gourash; Giselle Hamad; George M Eid; Samer Mattar; Ramesh Ramanathan; Emma Barinas-Mitchel; R Harsha Rao; Lewis Kuller; David Kelley Journal: Ann Surg Date: 2003-10 Impact factor: 12.969
Authors: Corey J Lager; Nazanene H Esfandiari; Yingying Luo; Angela R Subauste; Andrew T Kraftson; Morton B Brown; Oliver A Varban; Rasimcan Meral; Ruth B Cassidy; Catherine K Nay; Amy L Lockwood; Darlene Bellers; Colleen M Buda; Elif A Oral Journal: Obes Surg Date: 2018-11 Impact factor: 4.129
Authors: Ralph Peterli; Yves Borbély; Beatrice Kern; Markus Gass; Thomas Peters; Martin Thurnheer; Bernd Schultes; Kurt Laederach; Marco Bueter; Marc Schiesser Journal: Ann Surg Date: 2013-11 Impact factor: 12.969
Authors: Ana B Emiliano; Natalie R Lopatinsky; Marko Kraljević; Sei Higuchi; Ying He; Rebecca A Haeusler; Gary J Schwartz Journal: Am J Physiol Endocrinol Metab Date: 2022-06-06 Impact factor: 5.900
Authors: Mustafa Bektaş; Beata M M Reiber; Jaime Costa Pereira; George L Burchell; Donald L van der Peet Journal: Obes Surg Date: 2022-06-17 Impact factor: 3.479
Authors: Anne-Sophie van Rijswijk; Nienke van Olst; Winnie Schats; Donald L van der Peet; Arnold W van de Laar Journal: Obes Surg Date: 2021-05-17 Impact factor: 4.129
Authors: Nataly Echevarria-Castro; Kevin Silva-Parra; Marcos Polar-Trinidad; Juan C Sánchez-Vicente; Gustavo Salinas-Sedo; Carlos J Toro-Huamanchumo Journal: J Clin Med Date: 2022-08-11 Impact factor: 4.964
Authors: Ramon Rawache Lima; José Huygens Parente Garcia; Marina Seixas Studart; Fernando Siqueira Pinheiro; João Odilo Gonçalves Pinto; Leonardo Adolpho Sales; Lucas Marrocos Soares; Priscilla de Almeida Santos Journal: Arq Bras Cir Dig Date: 2022-08-26
Authors: Bianca M Leca; Uzma Khan; Jenny Abraham; Louise Halder; Emma Shuttlewood; Neha Shah; Hugh L Ellis; Simon J B Aylwin; Thomas M Barber; Vinod Menon; Harpal S Randeva; Georgios K Dimitriadis Journal: Obes Surg Date: 2020-08 Impact factor: 4.129
Authors: Hannes Beiglböck; Paul Fellinger; Tamara Ranzenberger-Haider; Bianca Itariu; Gerhard Prager; Alexandra Kautzky-Willer; Michael Krebs; Peter Wolf Journal: Obes Surg Date: 2020-06-13 Impact factor: 4.129